

FOI Request re Number of Patients Treated

Please detail the number of Oncology¹ patients treated² by your Trust with the stated therapies, during the time period **January 2019 to June 2019** inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	<90	0	<5	15	61	0
Nivolumab (Opdivo)	<40	<5	<5	<10	<5	10
Ipilimumab (Yervoy)	<10	0	0	<5	0	<5
Dabrafenib (Tafinlar)	26	0	9	17	0	0
Cabozantinib (Cabometyx)	<10	0	0	0	0	<10
Sunitinib (Sutent)	10	0	0	0	0	10
Pazopanib (Votrient)	10	0	0	0	0	10
Axitinib (Inlyta)	<5	0	0	0	0	<5
Atezolizumab (Tecentriq)	18	0	0	0	18	0
Sorafenib (Nexavar)	0	0	0	0	0	0
Tivozanib (Fotivda)	<5	0	0	0	0	<5
Lenvatinib (Lenvima)	0	0	0	0	0	0
Cetuximab (Erbix)	<5	<5	0	0	0	0
Everolimus (Afinitor)	0	0	0	0	0	0
Vemurafenib (Zelboraf)	0	0	0	0	0	0

1

Cancer Type	Diagnoses Codes (ICD10)
Head & Neck	C00-C14; C30-C32
Adjuvant Melanoma	C43 (treatment as additional treatment following primary)
Metastatic Melanoma	C43 plus C77, C78, C79
NSCLC	C34
RCC	C64

² Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).